The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.

The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.

Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.

Jeff Goff, RPh, MS, walks through how UPMC has operationalized IV iron therapy from screening through infusion, and outlines how his team approaches hypophosphatemia monitoring and patient selection in light of the FDA's boxed warning.

Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.

Pharmacy students can create greater career optionality by viewing the PharmD as a professional platform rather than a predetermined job title.